Avastin meets endpoint in Phase III second-line breast cancer trial
20 August 2009
Malini Guha
Please Login to read the full article.
20 August 2009
Malini Guha
mMalini.guha@informa.com
Genentech's (Roche) Avastin (bevacizumab) has met its primary progression-free survival (PFS) endpoint in a Phase III trial, RIBBON 2, the first to test it as a second-line treatment in combination with chemotherapy in women with metastatic HER2-negative breast cancer.
"We have learned for...
Please Login to read the full article.
RELATED CONTENT
NEWS
- EU shores up its support of Avastin in breast cancer
- US Capitol Capsule: Hope not enough for Avastin in MBC; Hamburg explains withdrawal
- Poor efficacy undermines Genentech metastatic breast cancer indication for Avastin
- FDA staff argue Avastin benefit in breast cancer not worth the risk
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
